Agent | Organism/cell type | Response | Reference |
---|---|---|---|
Dimaprit | Mice | Attenuates experimental autoimmune encephalomyelitis disease activity | [23] |
Dimaprit Histamine | Mouse activated T cells | Suppresses T cell proliferation, IL-6, IL-10, IL-17 and IFN-γ production | [24] |
H2 agonist Histamine (reversed by H2R antagonist) | Human neutrophils | Decreases neutrophil chemotaxis response | [44] |
H2 agonist Histamine (reversed by H2R antagonist) | Human T cells | Decreases T cell proliferation | [44] |
H2R agonists Histamine (reversed by H2R antagonist) | Human peripheral blood mononuclear cells | Inhibits secretion of IL-1 and IL-12, and stimulates production of IL-10 | |
Histamine (reversed by H2R antagonist) | Human peripheral blood mononuclear cells | Inhibits secretion of TNF-α | [30] |
Histamine (reversed by H2R antagonist) | Human DCs | Suppresses IL-12 production following lipopolysaccharide stimulation of DCs | [73] |
Histamine (reversed by H2R antagonist) | Human DCs | Promotes Th2 response, that is, upregulation of Th2 chemokine production, by immature DCs | [74] |
Histamine (reversed by H2R antagonist) | Rat mast cells | Suppresses TNF-α production | [33] |
Histamine (reversed by H2R antagonist) | Human umbilical vein endothelial cells | Stimulates production of IL-6 | [39] |